RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA Holdings Inc. (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today published its 2025 Sustainability Report. The report highlights IQVIA’s progress across its People, Public and Planet pillars, consistent with the company’s mission to accelerate innovation for a healthier world.
IQVIA’s 2025 Sustainability Report can be downloaded at: https://www.iqvia.com/-/media/iqvia/pdfs/about-us/sustainability/iqvia-2025-sustainability-report.pdf. Highlights from the report include:
- Investments in the company’s employees. IQVIA’s approximately 93,000 employees worldwide are central to delivering on the company’s mission. In 2025, IQVIA accelerated learning and development opportunities through expanded AI and data analytics upskilling, generating more than 230,000 employee engagements with AI learning resources. More than 2,000 employees participated in leadership development programs, strengthening IQVIA’s global leadership pipeline. Efforts to listen to and act on employee feedback continued to reflect strong employee engagement, with IQVIA exceeding Fortune 500 benchmarks across key metrics.
- Innovation in AI and technology. IQVIA advanced its AI strategy by expanding key partnerships to strengthen ecosystem interoperability and launching new AI-enabled solutions for internal use and external offerings. Guided by its AI Governance Council and Center for Defensible Data and AI, IQVIA remains committed to the responsible use of AI, with strong foundations in privacy, regulatory compliance and patient safety through its IQVIA Healthcare-grade AI® capabilities.
- Access to healthcare. Patients remain at the center of the research IQVIA supports. IQVIA continued to broaden access to clinical trials and improve the representation of underserved patient populations worldwide. In 2025, this included activating sites in Brazil and Argentina for a global acute coronary syndrome trial. Together, these sites enrolled 5,700 participants toward a global target of 47,000, helping ensure patients from the region are represented in large-scale cardiovascular research. IQVIA also expanded its global network of Prime Sites to 56 high-performing clinical trial centers, adding locations in Brazil, Italy and Japan.
- Global health. Leveraging its global scale and scientific expertise, IQVIA supported public health initiatives addressing some of the world’s most complex challenges. In 2025, IQVIA collaborated with governments, global health organizations and industry partners to respond to disease outbreaks, advance digital health strategies and strengthen healthcare systems.
- Environmental impact. IQVIA continued to reduce the environmental footprint of research and operations across its business. Its ongoing commitment to the My Green Lab® program, with 100% of its global laboratory network obtaining My Green Lab certification, remained a key element of IQVIA’s approach to more sustainable research. IQVIA also redesigned clinical trial test kits to use at least 98% recycled materials, reduced packaging emissions in cold chain logistics by 70% and expanded ISO 14001 and 45001 certifications across laboratories.
- External recognition. IQVIA was regularly recognized externally for its work. Among multiple notable awards in 2025, IQVIA was named to the 2026 Fortune® World’s Most Admired Companies™ list for the ninth year in a row and ranked No. 1 in its category for the fifth consecutive year; IQVIA scored “outstanding” — the highest distinction — in TIME’s inaugural ranking of the World’s Top HealthTech companies in 2025; IQVIA’s Health Research Space won the award for best mobile app for patient engagement from the MedTech Breakthrough Awards; IQVIA was the only clinical research organization to achieve top ranking in the Everest Group’s “AI-deas to Action: Operationalizing Generative AI in Life Sciences” report; and IQVIA received five Human Capital Management Excellence Awards® from Brandon Hall Group, recognizing its commitment to developing and investing in its employees.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 93,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
IQVIAFIN
Contacts
Kerri Joseph, IQVIA Investor Relations ([email protected])
+1.973.541.3558
Alissa Maupin, IQVIA Media Relations ([email protected])
+1.919.923.6785
